Taipei Exchange - Delayed Quote TWD

MegaPro Biomedical Co., Ltd (6827.TWO)

10.00
0.00
(0.00%)
As of 10:24:45 AM GMT+8. Market Open.
Loading Chart for 6827.TWO
  • Previous Close 10.00
  • Open 9.61
  • Bid 9.66 x --
  • Ask 9.94 x --
  • Day's Range 9.61 - 10.00
  • 52 Week Range 8.40 - 26.10
  • Volume 2,001
  • Avg. Volume 60,066
  • Market Cap (intraday) 647.209M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.68
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

www.megaprobio.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: 6827.TWO

View More

Performance Overview: 6827.TWO

Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6827.TWO
31.27%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
3.25%

1-Year Return

6827.TWO
55.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.96%

3-Year Return

6827.TWO
53.89%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
35.40%

5-Year Return

6827.TWO
74.75%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
90.16%

Compare To: 6827.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6827.TWO

View More

Valuation Measures

Annual
As of 6/9/2025
  • Market Cap

    634.26M

  • Enterprise Value

    552.24M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    45.30k

  • Price/Book (mrq)

    3.10

  • Enterprise Value/Revenue

    39.45k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -2.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 6827.TWO

View More

Company Insights: 6827.TWO

Research Reports: 6827.TWO

View More

People Also Watch